Saturday, 27 April 2013

Cutting cord early poses risk to babies

Experts say that cutting a baby's umbilical cord immediately after birth, which is currently standard practice, puts the child at risk or iron deficiency, which has been linked to brain development problems. Official guidelines are currently being examined - and professionals and campaigners say they should change. The reason for this is that leaving the cord attached for a few minutes would allow the blood within it to transfer to the baby, and raise the amount of iron within it's blood.

The existing guidance on cord-clamping was published in 2007, when the consensus was that cutting the cord immediately was the best option - something which had been the case for decades. Since then however, researchers have questioned whether that is still the case.

A paper from the Royal College of Obstetricians and Gynaecologists (RCOG) published in 2009, stated that babies whose umbilical cords are clamped immediately have lower iron stores for up to six months. Their suggestion is that the cord should not be cut until it has stopped pulsating naturally - anywhere between two and five minutes after birth; some hospitals have already changed their practice to meet this recommendation.

Commenting on the current re-evaluation of the guidance, an RCOG spokeswoman said: "The college recommends that the umbilical cord should not be clamped earlier than necessary and should always be based on clinical assessment of the situation." She went on to say: "Research has shown that delayed cord clamping of more than 30 seconds may benefit the newborn in reducing anaemia. It also allows time for the transfusion of placental blood to the newborn, especially in cases of premature birth." She did however add that there could be some cases where complications meant it was better to clamp the cord immediately.

Belinda Phipps, chief executive of the National Childbirth Trust (NCT) said: "When a baby is born about a third of the baby's blood is still in his/her cord and placenta. With no good evidence to support it, accepted practice is to accelerate the arrival of the placenta with an injection and clamp and cut the cord immediately, depriving the baby of this blood." She then said: "The NCT would like to see the default position become leaving the cord for a few minutes until it stops pulsating, unless the mother chooses to have an injection to speed the arrival of her placenta or unless the blood loss from the mother means her uterus must be encouraged, with drugs, to contract and expel the placenta quickly."

Prof Mark Baker, director of the centre for clinical practice at NICE, said all its guidelines were regularly updated to take into account developments in research. He also explained that all available evidence on the right time to clamp a newborn baby's cord is being considered, and their recommendation will represent what they believe is the best possible practice and will put mother and baby's safety first.

Jack

Friday, 19 April 2013

Explanation for cholesterol's damaging effect on the brain

A group of researchers, from the Linda Crnic Institute for Down's Syndrome and the Department of Neurology at the University of Colorado School of Medicine, have found that a single mechanism may underlie the damaging effect of cholesterol on the brain and blood vessels. High levels of blood cholesterol are known to increase the risk of both Alzheimer's disease and heart disease, but it has been unclear how cholesterol damages the brain to promote Alzheimer's disease.

Using insights gained from studying two much rarer disorders, Down's Syndrome and Niemann Pick-C disease, the researchers found that cholesterol wreaks havoc on the orderly process of cell division, leading to defective daughter cells throughout the body. In the study, published in the online journal PLOS ONE, Dr Antoneta Granic and Dr Huntington Potter show that cholesterol, particularly in the LDL form, causes cells in both humans and mice to divide incorrectly and distribute their already-duplicated chromosomes unequally to the next generation. The result of this is an accumulation of defective daughter cells with the wrong number of chromosomes and therefore the wrong number of genes. Instead of two copies of each chromosome, and thus two copies of each gene, some cells acquire three copies and some only one.

Granic and Potter's study of the effects of cholesterol on cell division included a prominent finding of cells carrying three copies of the chromosome (#21 in humans and #16 in mice) that encodes the amyloid peptide that is the key component of the neurotoxic amyloid filaments which accumulate in the brains of Alzheimer's patients.

Human trisomy 21 cells are significant because people with Down's syndrome have trisomy 21 in all of their cells from the moment of conception, and they all develop the brain pathology and many develop the dementia of Alzheimer's disease by the age of 50. Earlier studies by Granic, Potter and others have shown that up to 10% of cells in an Alzheimer's patient, including neurons in the brain, have three copies of chromosome 21 instead of the normal two. Because of this, Alzheimer's disease is in some ways a form of acquired Down's syndrome. Furthermore, mutant genes that cause Alzheimer's disease cause the same defect in chromosome segregation as is caused by cholesterol, thus indicating the presence of a common cell division problem in both familial and sporadic (non-familial) Alzheimer's disease. The new research also found trisomy 21 neurons in the brains of children with what, until now, was thought to be an unrelated neurodegenerative disease (Niemann Pick type C), caused by a mutation that affects cholesterol physiology. This result suggests that neurodegeneration itself might be linked to chromosome missegregation.

Identifying the specific problem caused by cholesterol will lead to completely new approaches to therapy for many human diseases, including Alzheimer's disease, atherosclerosis and possibly cancer, all of which show signs of defective cell division. Granic and Potter have already found a potentially simple approach to preventing cholesterol from causing cells to distribute their chromosomes unequally into their new daughter cells. Specifically, when cells in culture were treated with ethanol, the subsequent exposure to LDL cholesterol had no adverse effects on cell division, and each cell received the correct number of chromosomes.

Jack

Friday, 12 April 2013

Better oncogene understanding may lead to better cancer treatments

The Myc oncogene can disrupt the 24-hour internal rhythm in cancer cells, as several distinguished experts explained during their "Metabolic Pathway Regulation in Cancer" session at the 2013 American Association for Cancer Research meeting.

Timing of the body's molecular clock in normal cells synchronises the cellular need for energy with food intake during our sleep-wake cycle. Timing matters to the study of cancer in two ways; first, toxicity to some chemotherapy drugs is related to the time of day at which they are administered. For instance, a cancer drug called 5-fluorouracil is less toxic if given to a patient at night because the liver enzymes that detoxify it are more abundant at night. Second, several circadian rhythm genes have been implicated as tumour suppressors, although those exact connections are as yet unclear. Other researchers have also observed that many, but not all, cancer cell cultures lack proper circadian rhythm.

"Our hypothesis is that disrupting circadian rhythm benefits cancer cells by unleashing their metabolism from the constraints of the molecular clock," says Dr Brian Altman, one of the scientists involved. "In this regard, cancers don't sleep; they don't rest."

The study deals with the relationship of clock proteins in peripheral tissues associated with three types of cancer cells. The researchers surmise that Myc may affect circadian rhythm by promiscuously binding to promoter regions in key genes for maintaining circadian rhythm. In fact, using a well known genome browser they confirmed that Myc binds to circadian genes. The team also found that Myc upregulates another clock-regulated protein called NAMPT, potentially leading to dysregulated Sirt1 activity, another protein that is part of the complicated molecular clock. Inhibiting NAMPT downstream of Myc also led to changes in circadian gene expression, suggesting a role for the modulation of other proteins downstream of Myc in 'throwing a wrench in the clock's gears'.

Using cells from cultures of neuroblastoma, osteosarcoma, and hepatocellular carcinoma, which all overexpress Myc, they found that the abundance of Myc specifically upregulated the circadian protein Rev-erba. This protein in turn suppressed the oscillation of Bmal1 messenger RNA and decreased expression of the main clock protein Bmal1. What's more, the disrupted circadian oscillations in the Myc-expressing cancer cells could be partially rescued by inhibiting expression of Rev-erba.

"Our data suggests that Myc-driven cancers have altered circadian oscillation due to upregulation of Rev-erba and NAMPT, and that these Myc cancers may be good for chronotherapy," says Altman. "This work ties together the study of cell metabolism and cancer chronotherapy - If cells don't have to 'rest', they may replicate all the time, with no breaks at all." Another of the scientists involved, Annie Hsieh, said: "The understanding of these basic mechanisms from our work should lead to better cancer treatment strategies that reduce side effects and increase effectiveness."

Jack

Friday, 5 April 2013

Alzheimer's genetic markers identified

Genetic markers which could help highlight who is at risk from developing Alzheimer's disease have been identified by US scientists. The research identifies mutations that affect the build-up of tau proteins in the brain. UK experts said the study could help understand the changes that occur in the brains of Alzheimer's patients.

One of the new gene variants identified by the Washington University School of Medicine team was also shown to be linked to a small increased risk of developing Alzheimer's and a greater risk of cognitive decline.

Dr Alison Goate, who led the study, said: "We anticipate that knowledge about the role of these genes in Alzheimer's disease may lead to the identification of new targets from therapies or new animal or cellular models of the disease."

UK experts said the study adds to the number of genetic markers that have been linked to the development of Alzheimer's disease. Dr Doug Brown, director of research and development at the Alzheimer's Society, said: "In discovering new genes that have a link to Alzheimer's, this robust study helps scientists to better understand the way the brain changes when dementia develops. Research such as this may in the future help us to engineer treatments aimed at stopping such changes and therefore slowing or stopping the effects of dementia." He added: "These new gene markers, as important as they are, are likely to be a few of many that might affect a person's risk of developing Alzheimer's. However, it is important to stress that lifestyle factors also play a role, and research has shown that eating a balanced diet, exercising regularly, not smoking, and getting your blood pressure and cholesterol checked regularly are key ways to reduce your risk of dementia."

Jack